The FDA and the EMEA are testing a Pilot Process for Biomarker Qualification, which was created based on the specific need for new biomarkers in drug development. This Pilot Process needs to be tested and refined with multiple qualification proposals.
Several representatives will be on hand to answer your specific questions and requests for clarification about biomarker qualifications. To help us to properly prepare for this question and answer period, we request that registrants submit their questions in advance to Biomarkerwebinarquestions@diahome.org.
Registrants will also have the opportunity to submit questions during the webinar through an anonymous computerized Q&A function.
Several representatives will be on hand to answer your specific questions and requests for clarification about biomarker qualifications. To help us to properly prepare for this question and answer period, we request that registrants submit their questions in advance to Biomarkerwebinarquestions@diahome.org.
Registrants will also have the opportunity to submit questions during the webinar through an anonymous computerized Q&A function.
